Bambusa Therapeutics Inc BBTX

$16.58 +0.60 (3.75%)

Valuation

Market cap
819,657,000
Revenue TTM
$0
Net income TTM
$-41,087,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
148,206
Avg volume
—
Day's range
$15.35 – $16.61
Shares out
50,942,000
Stochastic %K
35%
Beta
—
Analysts
—
Price target
—

Price

Company profile

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and o...

Show more

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United States, Australia, New Zealand, China, Europe, and internationally. Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
(617) 848-6188
Website
https://www.bambusatx.com
Address
22 Boston Wharf Road, Floor 7, Boston, United States

Stocktwits

Veridionmarkets Nov 8, 5:49 PM
$BBTX IPO priced at 16 dollars on Oct 29. Per the Form 4 (accession 0001231919-26-001533, signed Nov 3), RA Capital, a 10% owner with a partner on the board, bought 453,820 shares in the open market on Oct 30, the first day of trading, at weighted averages of 14.23 and 14.92 dollars, about 6.6 million in total. Its funds then bought 2.5 million more shares at the 16 dollar offer price on Nov 2, about 40 million, and held 7,429,758 shares afterward. Filings show trades, not reasons.
0 replies
openmarketalerts Nov 4, 3:17 PM
Tue, Nov 3: cluster buys filed $BBTX Bambusa Therapeutics — 3 insiders bought $58.6M (Oct 30 – Nov 2) $STRZ Starz Entertainment — 3 insiders bought $177K (Nov 2) $OCFC Oceanfirst Financial — 3 insiders bought $278K (Oct 30 – Nov 3) $SYNX Silynxcom — 3 insiders bought $118K (Oct 29 – Nov 2) $TRTX Tpg Re Finance Trust — 3 insiders bought $299K (Oct 30) Open-market purchases from SEC filings. No stock grants, no option exercises, no pre-scheduled 10b5-1 plan trades.
1 replies